By Fineline Cube 
Medtronic plc (NYSE: MDT) announced financial results for its fourth quarter (Q4) and fiscal year 2026 (FY26), which concluded on April 24, 2026. The global medical technology leader delivered Q4 revenue of $9.8 billion, representing 6.6% organic growth, while achieving full-year FY26 revenue of $36.4 billion with 5.8% organic growth.
Quarterly Financial Performance Summary
| Metric | Q4 FY26 | Year-over-Year Change |
|---|---|---|
| Total Revenue | $9.8 billion | +6.6% organic |
| Cardiac Ablation Solutions | Not disclosed | +78% global (+124% US) |
| Cardiovascular | $3.8 billion | +10.1% |
| Medical Surgical | $2.4 billion | +5.1% |
| Neuroscience | $2.8 billion | +3.0% |
| Diabetes | $837 million | +8.1% |
All growth figures represent organic performance, excluding the impact of foreign currency fluctuations and acquisitions.
Business Group Performance Highlights
Cardiovascular (+10.1% to $3.8 billion)
- Cardiac Rhythm Management delivered mid-single-digit growth
- Cardiac Pacing Therapies and Defibrillation Solutions showed continued strength
- Micra platform achieved mid-teens growth
- OmniaSecure launched successfully in the US market with strong initial adoption
Medical Surgical (+5.1% to $2.4 billion)
- Acute Care & Monitoring led segment performance
- Endoscopy contributed significantly to growth
- Broad-based recovery across procedural volumes
Neuroscience (+3.0% to $2.8 billion)
- Steady performance across neurovascular and neuromodulation portfolios
- Consistent demand for chronic pain and movement disorder therapies
Diabetes (+8.1% to $837 million)
- Continued momentum in insulin delivery systems
- Strong international performance complementing US market share gains
Strategic Growth Drivers
- Cardiac Ablation Solutions emerged as the standout performer with 78% global growth, including an exceptional 124% increase in US revenue, reflecting strong adoption of next-generation ablation technologies for atrial fibrillation treatment
- Innovation Pipeline: Recent product launches, including OmniaSecure, demonstrate successful commercialization of R&D investments
- Procedural Recovery: Full normalization of elective and semi-elective procedures post-pandemic continues to benefit all business segments
- Geographic Diversification: Balanced performance across developed and emerging markets provides revenue stability
Full-Year FY26 Achievement
- Total Revenue: $36.4 billion
- Organic Growth: 5.8%
- Consistent Execution: Delivered steady quarterly performance throughout the fiscal year
- Market Leadership: Maintained #1 or #2 position in 25 of 27 product categories
The results reflect Medtronic’s successful execution of its strategic priorities, including innovation acceleration, operational excellence, and market expansion initiatives.
Forward‑Looking Statements
This brief contains forward-looking statements regarding Medtronic’s financial performance and market position. Actual results may differ materially due to risks including regulatory approvals, competitive dynamics, supply chain constraints, and macroeconomic conditions affecting healthcare spending.-Fineline Info & Tech